The amyloid-β pathway in Alzheimer's disease
Breakthroughs in molecular medicine have positioned the amyloid-β (Aβ) pathway at the
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
center of Alzheimer's disease (AD) pathophysiology. While the detailed molecular …
COVID-19 associated cognitive impairment: A systematic review
JWL Tavares-Júnior, ACC de Souza, JWP Borges… - Cortex, 2022 - Elsevier
Introduction COVID-19 has a wide range of clinical manifestations. Neurological
manifestations in COVID-19 patients were demonstrated during the pandemic, including …
manifestations in COVID-19 patients were demonstrated during the pandemic, including …
History and progress of hypotheses and clinical trials for Alzheimer's disease
PP Liu, Y Xie, XY Meng, JS Kang - Signal transduction and targeted …, 2019 - nature.com
Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …
memory loss along with neuropsychiatric symptoms and a decline in activities of daily life. Its …
Recent advancements in pathogenesis, diagnostics and treatment of Alzheimer's disease
Background: The only conclusive way to diagnose Alzheimer's is to carry out brain autopsy
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
of the patient's brain tissue and ascertain whether the subject had Alzheimer's or any other …
Altered bile acid profile associates with cognitive impairment in Alzheimer's disease—an emerging role for gut microbiome
Introduction Increasing evidence suggests a role for the gut microbiome in central nervous
system disorders and a specific role for the gut-brain axis in neurodegeneration. Bile acids …
system disorders and a specific role for the gut-brain axis in neurodegeneration. Bile acids …
Lessons learned from the fate of AstraZeneca's drug pipeline: a five-dimensional framework
Maintaining research and development (R&D) productivity at a sustainable level is one of
the main challenges currently facing the pharmaceutical industry. In this article, we discuss …
the main challenges currently facing the pharmaceutical industry. In this article, we discuss …
Alzheimer disease: epidemiology, diagnostic criteria, risk factors and biomarkers
The global prevalence of dementia is as high as 24 million, and has been predicted to
quadruple by the year 2050. In the US alone, Alzheimer disease (AD)–the most frequent …
quadruple by the year 2050. In the US alone, Alzheimer disease (AD)–the most frequent …
The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features
R Ossenkoppele, YAL Pijnenburg, DC Perry… - Brain, 2015 - academic.oup.com
A 'frontal variant of Alzheimer's disease'has been described in patients with predominant
behavioural or dysexecutive deficits caused by Alzheimer's disease pathology. The …
behavioural or dysexecutive deficits caused by Alzheimer's disease pathology. The …
Prevalence of amyloid PET positivity in dementia syndromes: a meta-analysis
Importance Amyloid-β positron emission tomography (PET) imaging allows in vivo detection
of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its …
of fibrillar plaques, a core neuropathological feature of Alzheimer disease (AD). Its …
Epidemiology of Alzheimer disease
The global prevalence of dementia is estimated to be as high as 24 million, and is predicted
to double every 20 years through to 2040, leading to a costly burden of disease. Alzheimer …
to double every 20 years through to 2040, leading to a costly burden of disease. Alzheimer …